[Clinical experience with a new peripheral vasodilator agent, in which are combined raubasine, and 2 ergot alkaloids in the treatment of peripheral diabetic angiopathy].
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D004338:Drug Combinations; D004876:Ergot Alkaloids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004878:Ergotamine / Q000008:administration & dosage / Q000009:adverse effects; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015016:Yohimbine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D004338:Drug Combinations; D004876:Ergot Alkaloids; D014665:Vasodilator Agents; D015016:Yohimbine; D004878:Ergotamine
Experiencias clínicas con un nuevo vasodilatador periférico, en el que se asocian raubasina y dos alcaloides del cornezuelo de centeno, en el tratamiento de la angiopatía diabética periférica.